Pharmaceuticals

Industry Forecast: Anthrax Vaccine Market to Generate $5.73 Billion Revenue by 2029

September 1, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#How Will the Anthrax Vaccine Market Evolve in Terms of Growth and Size by 2029?#_x000D_

The market size for intravenous iron drugs has experienced rapid expansion in recent years. Its projected growth trajectory sees it rising from a value of $3.44 billion in 2024, to $3.81 billion in 2025. This increase corresponds to a compound annual growth rate (CAGR) of 10.6%. The escalating prevalence of iron deficiency anemia, proliferating chronic diseases, a surge in healthcare spending, an aging populace, and an increasing occurrence of specific illnesses have been major factors contributing to this historical period growth._x000D_

_x000D_

The market for intravenous iron medications is projected to experience swift expansion in the ensuing years, catapulting to “$5.73 billion in 2029 with a compound annual growth rate (CAGR) of 10.8%. The anticipated growth during the forecast period could be due to government policies, advancements in the IV iron drugs sphere, rising demand for IV iron solutions, an uptick in research and developmental activities, and improved formulation and administration procedures. The forecast period is likely to witness developments such as advanced IV iron treatments, progress in drug formulation, a pivot towards more user-friendly IV iron treatments, strategic alliances, mergers and acquisitions, and breakthroughs in innovative drug delivery systems._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp_x000D_

_x000D_

#What factors are expected to fuel Anthrax Vaccine market growth in the coming years?#_x000D_

The escalating occurrence of contagious ailments is predicted to boost the anthrax vaccine market’s expansion. Contagious diseases are health conditions triggered by harmful microorganisms, inclusive of bacteria, viruses, parasites, or fungi. These diseases can transmit directly or indirectly between individuals, often leading to symptoms that vary in severity, sometimes leading to death, influenced by the pathogen and the person’s immune reaction. The rising occurrence of infectious diseases stems from demographic shifts worldwide, urbanization, environmental and land use changes, as well as alterations in human behavior. The anthrax vaccine is primarily employed to defend against anthrax and research is currently investigating its potential for wider use in warding off other infectious diseases through its immunogenic attributes and versatility. For example, the US-based nonprofit organization, the Council on Foreign Relations reported in February 2023 that up to 75% of newly identified or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases originated from zoonotic sources. Additionally, across the globe, zoonoses result in 2.7 million human deaths and 2.5 billion instances of illness every year. Hence, the escalating occurrence of diseases is propelling the anthrax vaccine market’s growth._x000D_

_x000D_

The intravenous iron drugs market covered in this report is segmented – _x000D_

_x000D_

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types_x000D_

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases_x000D_

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy_x000D_

_x000D_

Subsegments:_x000D_

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran _x000D_

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex _x000D_

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose _x000D_

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate_x000D_

_x000D_

#What Upcoming Trends Are Expected To Impact The Anthrax Vaccine Market Globally?#_x000D_

Prominent firms in the intravenous iron drugs market are putting their efforts into developing innovative therapies such as intravenous (IV) iron replacement therapy. They aim to enhance its effectiveness, safety, and influence on patient results. Intravenous (IV) iron replacement therapy is a medical procedure which administers iron directly into the bloodstream via an intravenous drip. This therapy is used to address iron deficiency and anemia, especially in individuals who are unable to adequately absorb or tolerate oral iron supplements. In June 2023, for instance, the U.S. Food and Drug Administration (FDA) gave approval to Daiichi Sankyo Company Limited, a pharmaceutical company based in Japan that is known for its inventive drug development and healthcare solutions. They received approval for Injectafer (ferric carboxymaltose injection), a treatment for iron deficiency in adults with heart failure who are categorized as New York Heart Association class II/III to boost their exercise capacity. Injectafer is a commonly used intravenous iron therapy renowned for rapidly restoring iron levels in patients who do not respond favorably or cannot bear oral iron supplements._x000D_

_x000D_

#What Are The Most Active Companies In The Anthrax Vaccine Market Today?#_x000D_

Major companies operating in the intravenous iron drugs market are AbbVie Inc., Sanofi S.A., Amgen Inc., Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., CSL Limited, Sandoz Group AG., Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Galenica Ltd., Dr.Reddy’s Laboratories, Hikma Pharmaceuticals plc, Zydus Lifesciences Limited, Biocon Limited, Kissei Pharmaceutical Co. Ltd., American Regent Inc., Akebia Therapeutics Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Mitsubishi Tanabe Pharma Corporation _x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report_x000D_

_x000D_

#Which Regional Markets Are Attracting The Most Investment In Anthrax Vaccine?#_x000D_

North America was the largest region in the intravenous iron drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_